David Zukoff, MD
Cardiovascular Disease · Tinton Falls, NJNPI 1023089778
Payments from drug & device makers
Across 635 payments — averaging $44.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$21K
- Novartis$2K
- Amgen$644
- Boehringer Ingelheim$478
- AstraZeneca$452
- Esperion Therapeutics, Inc.$408
- plus $4K from 31 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$18,20064%
- Food & beverage$9,87335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 120 | $20,730 |
| Novartis | 222 | $1,917 |
| Amgen | 35 | $644 |
| Boehringer Ingelheim | 27 | $478 |
| AstraZeneca | 28 | $452 |
| Esperion Therapeutics, Inc. | 14 | $408 |
| Amarin Pharma, Inc. | 31 | $401 |
| Boston Scientific | 21 | $366 |
| E.r. Squibb & Sons, L.L.C. | 20 | $345 |
| Biotronik Inc. | 7 | $334 |
| Merck | 15 | $316 |
| Abbott | 6 | $300 |
| Pfizer | 17 | $177 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $159 |
| Medtronic | 3 | $159 |
| Cardiofocus, Inc. | 1 | $144 |
| Novo Nordisk | 8 | $142 |
| W. L. Gore & Associates, Inc. | 9 | $140 |
| Vifor Pharma, Inc. | 5 | $94 |
| Philips North America LLC | 3 | $61 |
| Gilead | 4 | $59 |
| Irhythm Technologies, Inc. | 3 | $57 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Lilly USA, LLC | 3 | $48 |
| Bardy Diagnostics, Inc. | 5 | $45 |
| Lantheus Medical Imaging, Inc. | 2 | $44 |
| Lundbeck LLC | 3 | $44 |
| Cardiovascular Systems Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 3 | $39 |
| Astellas Pharma US Inc | 2 | $27 |
| Akcea Therapeutics, Inc. | 2 | $27 |
| Biosense Webster, Inc. | 1 | $26 |
| Bayer | 1 | $24 |
| Edwards Lifesciences | 1 | $21 |
| Biogen | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Vital Connect, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,373 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 237 | $267,539 |
| XareltoRivaroxaban | 121 | $154,002 |
| Repatha SureclickEvolocumab | 47 | $42,239 |
| EntrestoSacubitril/Valsartan | 35 | $34,131 |
| BrilintaTicagrelor | 22 | $24,873 |
| JardianceEmpagliflozin | 17 | $18,295 |
| Repatha PushtronexEvolocumab | 17 | $11,160 |
| Metoprolol Succinate | 227 | $4,491 |
| Nebivolol Hcl | 58 | $3,807 |
| Atorvastatin Calcium | 293 | $3,704 |
| Rosuvastatin Calcium | 207 | $2,878 |
| Ezetimibe | 93 | $2,605 |
| Metoprolol Tartrate | 130 | $1,564 |
| Olmesartan Medoxomil | 53 | $1,555 |
| Midodrine Hcl | 30 | $1,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $177 | $267,539237 claims |
| Johnson & JohnsonXarelto | $20,730 | $154,002121 claims |
| NovartisEntresto | $1,917 | $34,13135 claims |
| AstraZenecaBrilinta | $452 | $24,87322 claims |
| Boehringer IngelheimJardiance | $478 | $18,29517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Tinton Falls
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
- John CovaleskyManalapan$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.